Simultaneous Bilateral Bone Bridge Implantation in a Two-Year-Old Child with Atresia of the External Auditory canal: A Case Report

Thomas Mayr¹, Astrid Magele¹,², Philipp Schörg¹,², Georg M Sprinzl¹,²*

Abstract

Introduction: Active transcutaneous bone conduction implants are indicated for mild to moderate conductive or mixed hearing loss (intact inner ear and auditory nerve) for subjects 5 years or older. The aim of the here presented study was to share our results with the Bonebridge in a child aged 2 years at time of surgery. Especially the new generation of the implant being half of the size, a re-evaluation of the given indication for children 5 years or older is highly recommended.

Methods: case presentation

Results: At the age of one month bilateral auricle malformation as well as auditory canal atresia was diagnosed. The family history showed no further malformations and an uneventful pregnancy. The infant was provided with a Baha-Softband as well as speech therapy. Diagnostic BERA and MRI showed suitable anatomical structures allowing placement of an implant. The parents were counseled on available treatment options and the fact that the Bonebridge implantation would be off-label use due to the given indication age. Nonetheless, the parents insisted on the Bonebridge. At the age of 28 months the bilateral implantation (BCI 602) was performed within 40 minutes and without any intra- nor post-operative complications.

Conclusion: Based on the safe, easy and eventless implantation, the highly satisfactory results and the beneficial audiological outcomes, the authors propose to lower the implantation age based on available bone tissue allowing device placement. Similar as for Cochlear Implant recipients, a stable and early auditory input to ensure unrestricted speech development should be the major goal.

Keywords: Active transcutaneous bone conduction implant; Bonebridge BCI602; Bilateral atresia; Very young children; Early implantation; Bilateral implantation

Introduction

Implants using Bone Conduction (BC) already have a long history in the treatment of conductive hearing loss and recent technical advances have improved the variety of options to treat hearing loss. The Bonebridge (MED-EL, Innsbruck, Austria) is the first available active transcutaneous Bone Conduction Implant (BCI) featuring a sound processor that transmits sound energy transcutaneously to an internal coil. Subsequently the sound is transmitted to the floating mass transducer which transduces the signal into mechanical vibrations conducted to the mastoid bone via the cortical screws.
Currently the Bonebridge has its approval for implantation in adults as well as children aged 5 years or above with conductive or mixed hearing impairment and single-sided deafness being the main indications [1, 2]. Also current long-term data is showing satisfying results concerning safety and performance in children and adults in a 36 months follow-up [3]. With the change in shape of the internal part of the device (BCI 602) released in 2019 the drilling depth was reduced from 8.7 to 4.5 mm, giving new opportunities for different anatomical conditions in which the first generation may have been impossible to use, while having the same audiological and medical criteria [4, 5].

**Case Presentation**

The first admission of our patient occurred at the age of one month due to bilateral auricle malformation as well as auditory canal atresia. In the family history were no further malformations and the pregnancy was uneventful. To bridge the time until operation the infant was provided with a non-surgical bone conduction solution (Baha-Softband) as well as speech therapy. Unfortunately, the patient’s parents were not satisfied with the benefit and furthermore complained about the handling- and wearing difficulties of the toddler regarding keeping the device in place. Another point of concern was the constant stigmata the child had to experience and the fact that it therefore also retreated very much from social interactions with its peers. At 20 months of age a MRI, as well as a CT-Scan and a Brainstem Electric Response Audiometry (BERA) were made for further diagnostic purposes at our hospital. The BERA showed regular inner ear function on both sides (Figure 1), and the MRI revealed no malformations of the cerebellopontine angle, internal auditory meatus, cochlea and vestibular system. At the CT-Scan it was noticeable that beside the bilateral atresia of the outer ear channel the malformation of the left ossicular chain was more pronounced than on the right side coherent with the auricle malformation (Figure 2 a-d). The stapes was regularly developed on both sides. Furthermore, the CT-Scan showed well-pneumatized mastoid bones on both sides. After informing the parents about the different treatment options (Bone Anchored Hearing Devices (BAHA) and passive BCI Sophono) and the fact that the Bonebridge implantation would be off-label use due to the young age, the parents decided in favor of the Bonebridge as the most suitable option. The bilateral implantation (BCI 602) took place at the age of 28 months and was completed without any complications. We performed a retroauricular incision with a mucoperiosteal flap, uncovering the planum mastoideum, drilling the 4,5mm deep implant bed and finally placing the BCI-FMT with three standard screws and one emergency screw for both sides (Figure 3 a, b). Neither

![Figure 1](https://example.com/figure1.png)

**Figure 1:** Brainstem Evoked Response Audiometry (BERA) signals. Bone conduction BERA potentials were detected up to 20dB in the presented case.
Figure 2: Computed Tomography (CT) scan from left side, axial projection displaying Atresia of the auditory canal (a); left side, axial projection showing regular Inner Ear anatomy (b); right side, axial projection presenting Atresia of the auditory canal (c); right side, axial projection showing regular Inner Ear anatomy (d).

Figure 3: Shows the pre-op planning based on CT-images to ensure enough space for drilling and appropriate screw fixation (left side)/a,b). Intra-op photographs of the left side, showing the drilled implant bed without any sinus nor dura exposure and the final position of the BC-FMT with both screws in place (c,d). Most recent follow-up picture of the patient, showing the daily situs of the implant with the Audio Processor (SAMBA2) in place (left and right patient side)/(e,f).

sinus nor dura were explored nor compressed (Figure 3 c, d). The surgical time for bilateral implantation took from skin incision to final closing 40 Minutes. The girl was discharged to home care two days after surgery and the parents were advised to keep the incision area clean and dry. There were no issues during the outpatient checkup 13 days after surgery. On the same day the two processors were successfully fitted. Further follow-ups were made after one month, three months and half a year after surgery (Figure 3 e, f). The most recent check-up was carried out 18 months after surgery showing 100% speech understanding at 65dB (Figure 4). The parents reported that she was wearing her audio processors all waking hours and that she was no longer shy and withdrawn from other children. On the contrary, the parents believe, that their daughter appears to be at the same level of language development as her kindergarten peers.

Discussion

The Bonebridge as the first active transcutaneous bone conduction implant represents an effective treatment for conductive or mixed hearing impairment, without certain disadvantages of passive Bone-Anchored Hearing Devices (BAHD), especially in children where the skull is not yet sufficiently strong. Moreover, skin reactions, loss of osseointegration and revision surgery are less common when using the Bonebridge device, making it a safe and effective long-term hearing system even in very young patients. Especially the change in shape of the new model (BCI 602) widened the range of possible areas of application, particularly in children concerning the generally thinner bone in the possible surgical areas [1, 4, 6-9]. In literature satisfaction with the audiological outcome, aesthetic perception, and daily comfort of the Bonebridge is high. Especially pediatric patients report good results in communication and daily usage of the audio processor, leading to a noticeable improvement of the child’s speech development and social interactions, this holds also true to our experience with our own patients [4, 6, 10]. Our case shows that beside the age of the patient, especially anatomical circumstances like a well-pneumatized mastoid bone and sufficient bone thickness should support the decision for surgery. Facing that problem, 3D planning methods can be useful preoperatively for the implant decision and optimal anatomical location [11, 12].

Conclusion

Hearing Rehabilitation with the Bonebridge shows a significant audiological benefit for a variety of patients with conductive or mixed hearing impairment while showing safe and effective long-term results. Our case displays the successful use of bilateral Bonebridge in a 28 months old pediatric patient with excellent postoperative development and audiological results. Careful patient selection, considering the individual patient-anatomy, preoperative planning and
proper surgical techniques are the most important factors for postoperative satisfaction and a low complication rate. Based on the here presented results and high patient satisfaction, the authors propose to lower the present age limit of 5 years or older, to implantation based on available bone tissue allowing device placement. Similar as for Cochlear Implant recipients, were the earliest possible hearing rehabilitations allows the full auditory potential for normal development to be exploited.

**Statements**

**Statement of Ethics**

The presented case was part of a study with Institutional Review Board approval from the University Hospital St. Pölten, St. Pölten, Austria (Ethics Committee Decision no: GS1-EK-3/197-2021). The legal guardians of the child signed the informed consent form which was approved by the Ethics Committee.

**Conflicts of Interest Statement**

The authors have no conflict of interest to declare.

**Funding Sources**

No funding was received for this manuscript.

**Author Contributions**

Conception and design (TM, AM GMS); data acquisition (PS); data analysis (PS); interpretation of data for the work (TM, AM GMS); drafting the manuscript (TM); revision of the final manuscript (TM, AM GMS); approval of the final manuscript (ALL authors).

**Data Availability Statement**

Anonymized patient data is available on request from the corresponding author (GMS).

**References**


